Analysis and predictions AMED vs CHE
Loading...
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMED is a Buy and CHE is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMED’s FA Score shows that 1 FA rating(s) are green whileCHE’s FA Score has 1 green FA rating(s).
- AMED’s FA Score: 1 green, 4 red.
- CHE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMED’s TA Score shows that 4 TA indicator(s) are bullish while CHE’s TA Score has 4 bullish TA indicator(s).
- AMED’s TA Score: 4 bullish, 4 bearish.
- CHE’s TA Score: 4 bullish, 6 bearish.
Price Growth
AMED (@Medical/Nursing Services) experienced а +0.10% price change this week, while CHE (@Medical/Nursing Services) price change was +2.28% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +3.95%. For the same industry, the average monthly price growth was +0.99%, and the average quarterly price growth was +12.22%.
Reported Earning Dates
AMED is expected to report earnings on Jul 31, 2024.
CHE is expected to report earnings on Jul 24, 2024.
Industries' Descriptions
@Medical/Nursing Services (+3.95% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| AMED | CHE | AMED / CHE | |
| Capitalization | 3.02B | 9.7B | 31% |
| EBITDA | 129M | 414M | 31% |
| Gain YTD | -4.218 | 5.748 | -73% |
| P/E Ratio | 1170.50 | 35.73 | 3,276% |
| Revenue | 2.24B | 2.26B | 99% |
| Total Cash | 126M | 264M | 48% |
| Total Debt | 487M | 155M | 314% |
AMED | CHE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 63 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 87 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 12 | |
SMR RATING 1..100 | 90 | 36 | |
PRICE GROWTH RATING 1..100 | 55 | 54 | |
P/E GROWTH RATING 1..100 | 1 | 56 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CHE's Valuation (87) in the Medical Or Nursing Services industry is in the same range as AMED (98). This means that CHE’s stock grew similarly to AMED’s over the last 12 months.
CHE's Profit vs Risk Rating (12) in the Medical Or Nursing Services industry is significantly better than the same rating for AMED (100). This means that CHE’s stock grew significantly faster than AMED’s over the last 12 months.
CHE's SMR Rating (36) in the Medical Or Nursing Services industry is somewhat better than the same rating for AMED (90). This means that CHE’s stock grew somewhat faster than AMED’s over the last 12 months.
CHE's Price Growth Rating (54) in the Medical Or Nursing Services industry is in the same range as AMED (55). This means that CHE’s stock grew similarly to AMED’s over the last 12 months.
AMED's P/E Growth Rating (1) in the Medical Or Nursing Services industry is somewhat better than the same rating for CHE (56). This means that AMED’s stock grew somewhat faster than CHE’s over the last 12 months.
| AMED | CHE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 61% |
| Stochastic ODDS (%) | 2 days ago 65% | 2 days ago 66% |
| Momentum ODDS (%) | 2 days ago 57% | 2 days ago 48% |
| MACD ODDS (%) | 2 days ago 60% | 4 days ago 52% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 63% | 2 days ago 42% |
| Advances ODDS (%) | about 1 month ago 68% | 2 days ago 60% |
| Declines ODDS (%) | 2 days ago 65% | 8 days ago 45% |
| BollingerBands ODDS (%) | 2 days ago 67% | 2 days ago 61% |
| Aroon ODDS (%) | 2 days ago 77% | 2 days ago 31% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MSFU | 42.78 | 0.24 | +0.56% |
| Direxion Daily MSFT Bull 2X Shares | |||
| SYUS | 46.66 | 0.14 | +0.29% |
| Syntax Stratified US Total Market ETF | |||
| PGF | 14.73 | 0.01 | +0.07% |
| Invesco Financial Preferred ETF | |||
| GAL | 42.24 | -0.03 | -0.07% |
| SPDR® SSgA Global Allocation ETF | |||
| SCHX | 59.88 | -0.09 | -0.15% |
| Schwab US Large-Cap ETF™ | |||
AMED and
Correlation & Price change
A.I.dvisor tells us that AMED and ENSG have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AMED and ENSG's prices will move in lockstep.
| Ticker / NAME | Correlation To AMED | 1D Price Change % | ||
|---|---|---|---|---|
| AMED | 100% | -0.12% | ||
| ENSG - AMED | 25% Poorly correlated | +0.02% | ||
| OPCH - AMED | 24% Poorly correlated | -2.16% | ||
| TALK - AMED | 24% Poorly correlated | -2.23% | ||
| BKD - AMED | 22% Poorly correlated | -2.60% | ||
| EHAB - AMED | 22% Poorly correlated | -0.97% | ||
More | ||||